GlassScriptPhysician profile
James Michael Komer
NPI 1992819833
$1,637.15
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $293 · 2021: $498 · 2022: $344 · 2023: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $315.86 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $212.04 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $206.22 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $178.81 | 2021-2023 | Qelbree |
| Pfizer INC. | $162.63 | 2019-2023 | |
| Cranial Technologies, INC | $94.60 | 2019-2023 | Doc Band |
| Glaxosmithkline, LLC. | $73.55 | 2019-2021 | |
| Kaleo, INC. | $73.24 | 2021-2022 | |
| Adlon Therapeutics L.P. | $63.02 | 2020-2021 | |
| Corium, LLC | $60.08 | 2022-2023 | Azstarys |
| Seqirus USA INC | $53.88 | 2022-2023 | Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $25.57 | 2021 | |
| Neurelis, INC. | $23.26 | 2022 | |
| Genentech USA, INC. | $20.95 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.22 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $16.92 | 2023 | Immunocap |
| Vertical Pharmaceuticals, LLC | $13.62 | 2020 | |
| Abbvie INC. | $13.29 | 2020 | |
| Mylan Pharmaceuticals INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Komer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.